PMID: 6986750Mar 1, 1980Paper

Saralasin infusion in screening patients for renovascular hypertension

The American Journal of Cardiology
L R KrakoffK R Felton

Abstract

The usefulness of screening patients for renovascular hypertension by infusion of saralasin, a competitive antagonist of angiotensin II, was evaluated. Responses were compared in 19 patients with proved renovascular hypertension and in 34 without renovascular hypertension, as indicated by renal arteriography and renal venous renin studies. Saralasin infusion was carried out in the morning after furosemide, 80 mg by mouth, had been given the previous evening. Seventy-five percent of patients with and 12 percent of those without renovascular hypertension had a reduction in diastolic pressure of 5 mm Hg or more during saralasin infusion; only 45 percent of patients with and 6 percent of those without renovascular hypertension had a reduction of 10 mm Hg or greater during infusion. In comparison, 80 percent of patients with and 18 percent of those without renovascular hypertension had a positive intravenous pyelogram. The predictive value of a positive saralasin test (5 mm Hg or greater reduction in diastolic pressure) was calculated for varying prevalence rates of renovascular hypertension with use of Bayes theorem. The results indicate that when the prevalence rate of renovascular hypertension among hypertensive patients is 5 per...Continue Reading

References

Mar 27, 1975·The New England Journal of Medicine·D H StreetenT G Dalakos
Sep 1, 1978·The Journal of Pediatrics·E B TraininT W AvRuskin
Jul 31, 1975·The New England Journal of Medicine·B J McNeilS J Adelstein
Mar 1, 1977·Circulation Research·G H AndersonT G Dalakos
Mar 1, 1977·Annals of Internal Medicine·L BaerG S Williams
Jul 1, 1977·Annals of Internal Medicine·H M WilsonJ W Hollifield
Aug 1, 1977·Annals of Internal Medicine·G H AndersonD H Streeten
Jun 10, 1976·The American Journal of Medicine·D H StreetenT H Dalakos
Jul 15, 1976·The New England Journal of Medicine·A B Ribeiro, L R Krakoff

❮ Previous
Next ❯

Citations

Feb 1, 1990·Cardiovascular Drugs and Therapy·S C Textor
Apr 1, 1986·The American Journal of Medicine·F B MullerJ H Laragh
Jan 1, 1991·Clinical and Experimental Hypertension. Part A, Theory and Practice·B KutkuhnB Grabensee
Oct 1, 1982·The Journal of Urology·N A HalpernH A Mitty
Jan 1, 1987·Pharmacotherapy·M BorekW Frishman
Jun 11, 1983·The Medical Journal of Australia·S M GruenewaldE F Crocker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.